Skip to main content
Move the World.
coronavirus vaccine

Lead Image © Bloomicon.

As the novel coronavirus 2019-nCoV proliferates in China and spreads (to a much lesser extent) abroad — even reaching your correspondent's home base of Chicago; he's feeling fine, don't worry — the race is on for a new vaccine.

But creating a new vaccine is a laborious and expensive process, and when faced with a brand-new virus, the challenges are increased. Scientists must first understand what they are up against, and then they need to produce vast quantities of the ingredients necessary for a vaccine. Finally, even if it all works, the financial benefits can be minimal, leading many companies to shun investing in vaccines for emerging or uncommon diseases.

Vaccines work by priming the immune system to make antibodies for a particular disease. These large, y-shaped proteins then stick into the virus, disabling it or marking it for death by white blood cells. Vaccines use antigens, the protein signature of a virus, to stimulate the body to produce antibodies. Once the immune system has made them, the body will "remember" them and release a flood again as soon as the real virus attacks.

Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases (NIAID), wants vaccines for the Wuhan coronavirus to be ready for trial in three months. This is a monumental ask. But a handful biotech companies — with support from the Coalition for Epidemic Preparedness Innovations (CEPI), a public-private partnership which looks to accelerate vaccine development — are stepping up.

One of those companies, Cambridge-based Moderna Therapeutics, is harnessing the power of mRNA-based vaccines.

RNA vaccines use mRNA — essentially, cellular instructions translated from DNA — to tell the body's own cells to make antigens. Since RNA vaccines don't use the actual virus (or parts of it) to make the antigens, there is no need to grow and store huge quantities of them — an extremely expensive and time-consuming process that must be done specially for every disease's vaccine.

More importantly, mRNA is written in a simple genetic code. Researchers only need the genetic code of a pathogen to create potential mRNA antigens. It's basically a plug-and-play model, which means RNA vaccines can be created in bulk: cheaper, faster, and with standardized methods. It also means you can rapidly shift production to a new pathogen or new antigen candidate by inserting a new code.

Like, say, a novel coronavirus.

Moderna already has an animal-tested vaccine for Middle East respiratory syndrome (MERS), which is caused by a similar coronavirus. Theoretically, Moderna can substitute the code for their MERS vaccine with one from 2019-nCoV to create the new vaccine.  "It was a really, really hard scientific challenge to make the first one, but once you get the first one working, the next one becomes really easy: You get the sequence, and this is just another one," Stéphane Bancel, the CEO of Moderna, told Science Mag.

If the vaccine works, Moderna could prepare vast amounts of it: up to 100 million doses a year, if it dedicated all its resources to it, according to Bancel. This would be orders of magnitude greater and faster than traditional vaccine development, and such a feat would prove RNA vaccines' ability to be rapidly developed, scaled, and deployed.

If it works. Trials are expected to begin in three months.

Up Next

Public Health
The Coronavirus Fatality Rate: Explained
What is the coronavirus fatality rate
Public Health
The Coronavirus Fatality Rate: Explained
Your guide to understanding the confusing and contradictory coronavirus fatality rates.

Your guide to understanding the confusing and contradictory coronavirus fatality rates.

Outer Space
MIT Unveils Simulation to Help Stop an Asteroid Impact
Asteroid Impact
Outer Space
MIT Unveils Simulation to Help Stop an Asteroid Impact
MIT has developed a simulation to determine the most appropriate way to stop an asteroid impact if one of the space rocks is headed toward the Earth.

MIT has developed a simulation to determine the most appropriate way to stop an asteroid impact if one of the space rocks is headed toward the Earth.

Future of Medicine
The First Universal Flu Vaccine Could Be Coming Soon
The First Universal Flu Vaccine Could Be Coming Soon
Future of Medicine
The First Universal Flu Vaccine Could Be Coming Soon
After flu season, vaccines are outdated and researchers must predict next year’s virus. But soon, we may have a universal flu vaccine that doesn't expire.

After flu season, vaccines are outdated and researchers must predict next year’s virus. But soon, we may have a universal flu vaccine that doesn't expire.

Fighting Superbugs with Viruses
Fighting Superbugs with Viruses
Watch Now
Fighting Superbugs with Viruses
This Yale scientist's experimental treatment is a Texas woman's last resort.
Watch Now

Ben Chan searches sewers, lakes, and pig farms all around the world for bacteriophages (bacteria-destroying viruses) that could help fight antibiotic-resistant bacteria, also known as “superbugs.” Paige is a young woman in Texas with cystic fibrosis who is suffering from a drug-resistant infection; Ben’s experimental phage therapy is her last resort. We follow Ben as he travels from his laboratory at Yale to Lubbock,...

Coded
Disrupting Money
Disrupting Money
Watch Now
Coded
Disrupting Money
Can a bitcoin entrepreneur on house arrest convince the world it’s the currency of the future?
Watch Now

Charlie Shrem went from multi-millionaire to having almost nothing. Shrem was a Bitcoin pioneer. And it paid off big time. Until he was sent to jail for allowing a customer to resell bitcoin on Silk Road. Now, he’s out and wants to convince the world that Bitcoin is the future of finance.

The New Space Race
Preparing for Outer Space
Preparing for Outer Space
Watch Now
The New Space Race
Preparing for Outer Space
As the tech side of space travel advances, an annual gathering focuses on life off of planet earth.
Watch Now

Twenty years from now, humans could live in space permanently. As companies work feverishly to develop the tech needed for this galactic future, the New Worlds annual gathering brings together space lovers of all ages to brainstorm, fantasize and—more importantly—prepare for life off Earth.

Science
A Regulatory Fight Is Brewing Over Experimental Stem Cell Therapies
A Regulatory Fight Is Brewing Over Experimental Stem Cell Therapies
Science
A Regulatory Fight Is Brewing Over Experimental Stem Cell Therapies
New proposed regulations from the FDA would effectively shut down private stem cell clinics in the U.S.
By Mike Riggs

New proposed regulations from the FDA would effectively shut down private stem cell clinics in the U.S.